UCSF HIV Immunotherapy Trial Shows 7 of 10 Patients Controlled Virus After Stopping Treatment

HIV Research Just Had a Real Moment. Here's What Actually Happened.

A clinical trial led by Dr. Steven Deeks and Dr. Rachel Rutishauser at UC San Francisco — published December 1st in the journal Nature on World AIDS Day — tested whether a combination of immunotherapy agents could train the human body to control HIV on its own, without daily antiviral medication.

The results: 7 out of 10 participants kept the virus at low or undetectable levels for months after stopping antiretroviral therapy (ART). Normally, when an HIV-positive person stops their medication, the virus rebounds within roughly two weeks. Only 3 of the 10 experienced that typical rapid rebound, according to UCSF.

One patient had zero detectable virus for more than 18 months after stopping treatment.

What the Treatment Actually Was

This wasn't one magic shot. It was a structured, multi-step regimen.

First, patients received a therapeutic vaccine designed to activate T cells — the immune system's virus-hunters — to go after dormant HIV hiding in the body. Then they received a cocktail of broadly neutralizing antibodies (bNAbs) to reduce active virus levels. Finally, another round of antibody infusions was administered as they were taken off ART, with close clinical monitoring throughout, according to amfAR, the Foundation for AIDS Research, which co-funded the trial.

The goal was to hit HIV from multiple angles simultaneously: flush out the hidden reservoir, neutralize what's circulating, and prime the immune system to take over long-term.

What Mainstream Coverage Is Leaving Out

The New York Times framed this primarily as a story about a "single infusion" — which is misleading. This was a coordinated multi-stage regimen, not one shot. The single-infusion framing makes it sound simpler and more dramatic than it is, while also underselling the real complexity of what's required to make this work.

The NYT also leaned heavily on comparisons to cancer CAR-T therapy to generate excitement. Fine as a reference point, but HIV and blood cancer are different beasts. That framing risks overpromising to the 40 million people worldwide living with HIV.

Most coverage missed the mechanistic findings. The amfAR analysis goes deeper — researchers studied why some patients controlled the virus and others didn't. The results showed it wasn't about having more virus-killing T cells per se. The distinguishing factor between "controllers" and "non-controllers" was more nuanced, pointing toward specific immune response quality factors. That distinction matters for developing the next generation of this therapy.

The Injectable Parallel Story Nobody's Connecting

A second UCSF study published in JAMA on March 6, 2025 found that long-acting injectable antiretroviral treatments work just as well for difficult-to-treat patients as daily pills do for compliant patients.

Dr. Matthew Spinelli, assistant professor at UCSF's Division of HIV, Infectious Diseases and Global Medicine, led that study. His team tracked 370 patients — many of them homeless, dealing with substance use disorder, or otherwise unable to maintain a daily pill regimen. They gave these patients monthly or bimonthly injections of long-acting cabotegravir and rilpivirine instead.

Result: more than 98% of participants in both groups achieved viral suppression after 48 weeks. According to Spinelli, "We've had folks who struggled for years and when we put them on injectables, it's like magic."

The FDA approved the long-acting injectable combo back in 2021 — but only for patients who were already controlled on pills. This study challenges that restriction. The data says it works just as well for the hardest-to-treat population.

The Money Behind This

The immunotherapy trial was funded through a $20 million, five-year partnership between amfAR and UCSF, launched in 2015. The NIH's National Institute of Allergy and Infectious Diseases also backed the injectable study.

Nearly a dozen pharmaceutical companies collaborated on the immunotherapy trial. That level of industry involvement signals commercial interest, which speeds development but also means pricing conversations are coming. If this therapy eventually works at scale, the cost question will be enormous.

What This Means for Real People

HIV affects 40 million people globally. In the United States, roughly 1.2 million people are HIV-positive, according to the CDC. Daily antiretroviral therapy has made HIV manageable — but it's lifelong, it's expensive, and it requires near-perfect adherence.

A therapy that trains your own immune system to suppress the virus — even if it's not a full cure — would be transformational. No more daily pills. No more worrying about a missed dose. And for the millions who can't maintain a daily regimen due to poverty, housing instability, or addiction, the injectable research offers an immediate option.

Dr. Deeks said plainly, according to UCSF: "I do believe we are finally making real progress towards developing a therapy that may allow people to live a healthy life without the need of life-long medications."

The trial was small — 10 patients, no control arm. Nobody serious is calling this a cure. But in medical research, proof-of-concept in humans is the hard part. They just cleared that bar.